Long-term Vascular, Functional and Morphological Changes in Glaucoma and Ocular Hypertensive Patients
Launched by MARIO STIRPE · Feb 13, 2025
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This is an observational study involving patients with glaucoma, those with ocular hypertension and healthy subjects.
The aim of the study is the long term evaluation of functional, vascular and morphological changes in glaucoma and ocular hypertensive patients, compared to healthy subjects, to analyze the temporal relationship of these changes.
Secondary aims of the study are:
* evaluating the effect of age on functional, morphological and vascular changes and their relationship,
* evaluating the effect of myopia on functional, morphological and vascular changes and their relationship,
...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of primary glaucoma (open or closed angle) or secondary glaucoma (pseudoexfoliative or pigmentary) defined by the presence of a glaucomatous defect of the optic nerve and/or a perimetric glaucomatous defect as defined by the European guidelines
- • Diagnosis of ocular hypertension (defined by the presence of intraocular pressure values≥22 mmHg, optic nerve and visual field examination within normal limits)
- • No Optic nerve disease and IOP\<21mmHg for healthy subjects
- • Age\>18 years
- • Able to read and sing the informed consent form
- Exclusion Criteria:
- • 1. BCVA \<5/10
- • 2. Previous eye surgery, except glaucoma surgery or removal of cataracts performed more than 6 months prior to enrollment
- • 3. Other pathologies that can cause alterations of the optic nerve or visual field defects
- • 4. Presence of maculopathies
- • 5. Inability to perform visual field tests
- • 6. Opacity of the dioptric media such that it is not possible to perform reliable OCT and OCTA of acceptable quality
About Mario Stirpe
Mario Stirpe is a distinguished clinical trial sponsor dedicated to advancing medical research and improving patient outcomes through innovative clinical studies. With a strong focus on collaboration and ethical practices, the organization specializes in a range of therapeutic areas, employing rigorous methodologies to ensure the highest standards of trial integrity and data accuracy. By fostering partnerships with healthcare professionals, research institutions, and regulatory bodies, Mario Stirpe is committed to accelerating the development of effective treatments and contributing to the advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Novara, , Italy
Genoa, , Italy
Milan, , Italy
Rome, , Italy
Sassari, , Italy
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported